共 24 条
- [1] Plasma and Brain Levels of PYMS0028 (Cogane™) Associated with Neurorestorative Efficacy in Rodent and Primate Models of Parkinson's Disease: Translation to Once Daily Dosing in HumansNEUROLOGY, 2010, 74 (09) : A393 - A393Fox, SusanJohnston, Tom H.Koprich, James B.Huot, PhilippeWard, Caroline L.Meyers, NickHowson, PatrickBrotchie, Jonathan
- [2] PYM50028, an orally active neurotrophic factor inducer, is neurorestorative following MPTP-administration in a mouse model of Parkinson's diseaseMOVEMENT DISORDERS, 2009, 24 : S353 - S353Johnston, T. H.Koprich, J. B.Brotchie, J. M.Howson, P. A.Orsi, A.
- [3] Safety, tolerability and pharmacokinetics of Cogane™ (PYM50028) studied over 28 days in healthy subjects and patients with mild-moderate Parkinson's diseasePARKINSONISM & RELATED DISORDERS, 2009, 15 : S85 - S85Priestley, A.Barker, R.Hickling, R.Locker, J.Ward, C.Howson, P.Meyers, N.
- [4] The time-course of disease modifying effects of the neurotrophic factor inducer, PYM50028, in the MPTP-mouse model of Parkinson's diseaseMOVEMENT DISORDERS, 2013, 28 : S359 - S359Johnston, T. H.Koprich, J. B.Reyes, M. G.Meyers, N. L.Ward, C. L.Hickling, R. I.Howson, P. A.Brotchie, J. M.
- [5] PYM50028 restores dopamine transporter (DAT) levels in striatal dopamine terminals in a MPTP-lesioned mouse model of Parkinson's diseaseMOVEMENT DISORDERS, 2006, 21 : S643 - S643Visanji, N. P.Johnston, T. H.Brotchie, J. M.Hatton, S. L.Callizot, N.Orsi, A.Rees, D.
- [6] Antiparkinsonian action of a δ opioid agonist in rodent and primate models of Parkinson's diseaseEXPERIMENTAL NEUROLOGY, 2001, 172 (01) : 189 - 198Hille, CJFox, SHManeuf, YPCrossman, ARBrotchie, JM
- [7] Prior treatment with PYM50028, an orally active neurotrophic factor modulator in development for Parkinson's disease, reduces L-Dopa induced dyskinesia in MPTP-lesioned macaquesMOVEMENT DISORDERS, 2011, 26 : S281 - S282Johnston, T. H.Fox, S. H.Howson, P. A.Brotchie, J. M.
- [8] PYM50028, a novel, orally active neurotrophic factor inducer, protects and reverses the neuronal damage induced by MPP+ in mesencephalic neuronal cultures and by MPTP in a mouse model of Parkinson's diseaseMOVEMENT DISORDERS, 2007, 22 : S18 - S18Visanji, N. P.Johnston, T. H.Callizot, N.Orsi, A.Rees, D.Brotchie, J. M.
- [9] PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's diseaseFASEB JOURNAL, 2008, 22 (07): : 2488 - 2497Visanji, Naomi P.Orsi, AntoniaJohnston, Tom H.Howson, Patrick A.Dixon, KimberlyCallizot, NoelleBrotchie, Jonathan M.Rees, Daryl D.
- [10] Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinson's DiseaseJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 369 (03): : 364 - 374Howson, Patrick A.Johnston, Tom H.Ravenscroft, PaulaHill, Michael P.Su, JinBrotchie, Jonathan M.Koprich, James B.